Houston organization plans to launch health tech accelerator in 2022

ready to grow

Proxima Clinical Research has its New Year's resolution and is ready to start working hands on with health tech startups. Graphic via proximacro.com

A contract research organization based in Houston has announced its new accelerator program aimed at helping startups quickly grow their health tech businesses.

Proxima Clinical Research released details of M1 MedTech, which expects to launch early next year. The CRO has raised funds to launch and invest in members of the inaugural cohort.

“Our goal is to move these companies substantially forward in a short amount of time,” says Kevin Coker, CEO of Proxima, in a news release. “Proxima is in a unique position to leverage our experienced team of regulatory, quality, and clinical experts. We won’t be working at arm’s length from these companies. We will be a big part of what they do every day.”

The program will focus on a small group of companies and the Proxima team will provide hands-on support, including instruction, workshops, and one-on-one mentoring.

“This will be a unique experience for all parties involved, as Proxima is also a young, yet established, company that is now creating a program to assist companies at an earlier stage,” says Larry Lawson, co-founder of Proxima, in the release. “Our experience in the CRO realm and ability to provide coaching in clinical, regulatory, quality, and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and provide more life-saving technology to the public.”

Kevin Coker and Larry Lawson co-founded Proxima in 2017. Photos courtesy

The accelerator will target Class II and III medical devices for its initial cohort. In the future, Proxima plans to expand to include an even more extensive incubator focused solely on Class III devices, according to the release.

“M1 will be a place where startups can go to receive concrete resources to further their development. The participant success is our sole focus, and the ultimate goal is to have a substantial impact on the ideation-to-market process for Class II and Class III medical devices,” says Isabella Schmitt, director of regulatory affairs at Proxima and a principal at M1, in the release. “Proxima’s specific expertise alongside our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to market and beyond.”

The M1 MedTech applications will open online in the spring.

“We don’t view M1 as competitive to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a personalized program where companies have a dedicated touch point throughout the process,” says Sean Bittner, director of programs at M1 MedTech, in the release. “We will also provide specific, tailored connections and resources vetted by our team through professional partnerships, not just a general list of industry contacts.”

This week's roundup of Houston innovators includes Stephanie Campbell of HAN and The Artemis Fund, Larry Lawson of Proxima Clinical Research, and Vanessa Wyche of the Johnson Space Center. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from medical device development to fintech — recently making headlines in Houston innovation.

Stephanie Campbell, managing director of the Houston Angel Network and general partner at The Artemis Fund

Local investment leader talks trends in Houston venture capital activity

Stephanie Campbell joins the Houston Innovators Podcast last week to share some trends in early-stage investing. Photo courtesy of HAN

There were so many question marks at the beginning of the pandemic, especially for startup funding. Stephanie Campbell, who manages the most active angel network as well as a venture capital fund, says no one was sure how anything was going to pan out. Now, looking back on last year, VC did ok, she says on the Houston Innovators Podcast, and the Houston Angel Network saw membership growth.

"I think that given the markets with quite a bit of liquidity, people were looking for new and interesting ways to invest and make a return," Campbell says on the podcast. "In 2020, we actually grew by 30 percent and are up to 130 members of the Houston Angel Network and are continuing to grow through 2021."

Campbell shares more of her observations on the show and what she's focused on next. Click here to read more and stream the episode.

Larry Lawson, co-founder of Proxima Clinical Research

Larry Lawson joined InnovationMap for a Q&A about his startup's recent exit, his role on the boards of five med device companies, his investment activity, and more. Photo courtesy of Larry Lawson

When Larry Lawson started his career in the medical device industry, it was hard to get funding. The health tech founder and investor says if it wasn't oil or real estate, banks couldn't understand well enough to make a loan. So, he bootstrapped, raised from friends and family, and found venture capital support for his business endeavors over the years. Now, he's celebrating a $1.4 billion exit of his last business, Preventice Solutions, a deal that closed earlier this year.

The ecosystem in Houston has changed, he says, and he's seen it evolve as the Texas Medical Center grew and the Rice Business Plan Competition brought impressive student innovators from all around the globe.

"The health science community here in Houston is now known all over the world," he tells InnovationMap. "It's gonna just continue to grow and develop, and I hope to be a part of continue to be a part of it." Click here to read more.

Vanessa Wyche, director of Johnson Space Center

Vanessa Wyche is the first Black woman to lead a NASA center. Photo courtesy of NASA

For the first time, NASA has a Black woman at the helm of a space center. Vanessa Wyche has been named director of Johnson Space Center in Houston after serving as acting director since May 3.

"Vanessa is a tenacious leader who has broken down barriers throughout her career," Pam Melroy, deputy administrator of NASA, says in a news release. "Vanessa's more than three decades at NASA and program experience in almost all of the human spaceflight programs at Johnson is an incredible asset to the agency. In the years to come, I'm confident that Houston will continue to lead the way in human spaceflight."

As director of Johnson Space Center, Wyche now leads more than 10,000 NASA employees and contractors. Click here to read more.

Larry Lawson joined InnovationMap for a Q&A about his startup's recent exit, his role on the boards of five med device companies, his investment activity, and more. Photo courtesy of Larry Lawson

Fresh off a $1.4B exit, this Houston innovator is focused on funding medical device tech

Q&A

Earlier this year, Houston-based serial entrepreneur Larry Lawson celebrated the exit of his medical device company, Preventice Solutions, which he sold to Boston ScientificBoston Scientific in a $1.4 billion deal.

Nowadays, Lawson is laser focused on investing in the Houston innovation ecosystem, particularly in medical device, as well as working on Proxima Clinical Research, a contract research organization in the Texas Medical Center he co-founded with Kevin Coker.

Lawson joined InnovationMap for a Q&A about the exit, his role on the boards of five med device companies, and his investment activity. He also shares how he sees the impact of COVID-19 and where Houston's burgeoning innovation ecosystem is headed.

InnovationMap: Earlier this year you saw an exit for your company Preventice Solutions, a company focused on the development of mobile health solutions and remote monitoring, which was sold to Boston Scientific in a $1.4 billion deal. What did this deal mean to both you and the company?

Larry Lawson: It validated what I started back in 2004. I had an idea, And I moved forward on my idea — in the beginning completely financed that idea myself. I tried to raise funds, and it was very difficult here in Houston back in 2004 to do that. I put my money, you might say, where my mouth was and I started the company and funded it and built it to a point to where we attracted some venture capital from one of the world's largest VC groups out of California called Sequoia Capital. That allowed me to really increase our exposure and our footprint nationally. And it just grew and grew and eventually Boston scientific got interested in the company, along with Merck, a pharmaceutical company, and they bought smaller pieces of the company.

Then at the end of the year of 2020, Boston Scientific made a play to acquire the company completely. Frankly, it have been better. I would have never dreamt that my original company would be worth that much and sell for that much. So it was very nice for not only me, but for many other people that were employed by Preventice, because as a founder of the company, I knew how important it was to share equity with the people that really make the company run and make it run well.

IM: I noticed that you’re on the board of several Houston health tech startups — most of which I’ve covered on InnovationMap. What do you look for in a company before joining the board and what role do you play for the companies’ growth?

LL: First of all, I look at the people who are in the company — from top level executive level all the way down, even including the existing board members of the company. I only invest in medical device companies. That's what I know, and that's why I've spent over 50 years in, and I feel like I know it very well. I do not venture far off of that line or that path at all.

I look for a strong operating group. I look for strong leadership — and if I can bring even stronger leadership and have them get from point A to point B, I like to get involved. Given my medical as the chairman of the company.

IM: You started your investment firm in 2018 — what inspired you to create LAWALA Capital and what do you look for in potential portfolio companies?

LL: I really limit my investments to the medical device segment of health care. LAWALA is just me — it's the first two letters of all three of my names: Larry Wayne Lawson. How I got into investing and starting companies is I see opportunity, and I see voids in the industry.

IM: Speaking of, you founded Proxima Clinical Research in 2017, which has a very hands-on approach to accelerating health tech innovation. Why did you decide to start that up?

LL: I saw a void in the clinical research industry, specifically at the medical center here, the largest medical center on the face of the earth. And it was doing all of this attracting all of these companies, all of these health science companies into Houston, and they were building and budding their companies, but there was no centralized clinical research company to be there for them.

I thought, "my gosh, somebody ought to do this." Well, I'm a doer. So, I went to the powers to be at the medical center and got their approval to be the founder of a company, called Proxima Clinical Research, and the key is putting it right there in the heart of the largest medical center in the world.

It's been really, really good for these companies who are coming into Houston to take advantage of the life science growth that's taking place here in Houston.

IM: How did COVID-19 affect the work that you do?

LL: COVID really did not affect our business that greatly. It affected the investments that I was doing. I pulled back and cut my, expenses and that, because I just needed to see, you know, how the COVID thing would shake out. I'm watching my investments a lot closer today, and think that it's affected the startup companies, more because to be a startup company, you have to go out and find investors to invest in your company. And I think that process has been slowed, I won't say considerably, but I think it's been slowed quite a bit over the past year and a half.

It just so happens that in the industry that I've been in, which is patient monitoring — cardiac arrhythmia monitoring — COVID has heightened patient monitoring more than anything else. What we learned from COVID is that we've got to be more in tune ourselves than ever before in monitoring all aspects of ourselves. What has come out of this COVID pandemic is telemedicine, which has struggled for years, now all of a sudden telemedicine is on the tip of everyone's tongue.

And I think that's one reason why you see the big companies — the multinational, multi-billion dollar companies — getting more in patient monitoring.

IM: Houston is home to the largest medical center in the world — but it’s often times not listed as a top city for medical innovation. Is that changing? And if so, how?

LL: When the medical center purchased the old Nabisco building and turned that into a technology center and a startup center, it changed the whole complexion of the device and medical startup community here in Houston. We've had a lot of former development here through MD Anderson in oncology, but we'd never had very much in devices. Now, we have companies coming from Europe and Asia coming to Houston to promote their technology and the devices that they have built.

The Rice Business Plan Competition is the largest in the United States. We fund more startup companies out of RBPC. I'm talking Harvard, MIT, Stanford, Berkeley — Houston is number one. And that has a lot to do with what has happened in the medical center over the past seven or eight years.

IM: What more do we need, now that we've come this far to really push us into that innovative healthcare city status?

LL: Well, I think what we need is for investors investing in healthcare and not oil and dirt. For years and years, the whole economy was driven by oil and gas and real estate. And I can remember starting my first company, the early eighties, I went to banks to borrow money to start my first company, and all I wanted was $200,000. Well, that was still a lot of money back then, but they would literally fall asleep on me because they couldn't understand and didn't understand exactly what I wanted to do. And so I wound up having to fund myself use my friends and family as investors, but that's changed quite a bit. The health science community here in Houston is now known all over the world. It's gonna just continue to grow and develop, and I hope to be a part of continue to be a part of it.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University MBA programs rank among top 5 in prestigious annual report

top of class

Rice University’s Jones Graduate School of Business MBA programs have been ranked among the top five in the country again in The Princeton Review’s 2025 Best Business Schools rankings.

The university's MBA program in finance earned a No. 3 ranking, climbing up two spots from its 2024 ranking. Finance MBA programs at the University of Virginia's Darden Graduate School of Business and New York University's Leonard N. Stern School of Business were the only ones to outrank Rice, claiming No. 2 and No. 1 spots, respectively.

Rice's online MBA program was ranked No. 5, compared to No. 4 last year. Indiana University's Bloomington Kelley School of Business' online program claimed the top spot.

“These rankings reflect the commitment of our faculty and staff, the drive and talent of our students and the strong support of our alumni and partners,” Peter Rodriguez, dean of Rice Business, said in a news release. “They are exceptional honors but also reminders — not just of our top-tier programs and world-class faculty and students but of our broader impact on the future of business education.”

Rice also ranked at No. 6 for “greatest resources for minority students."

The Princeton Review’s 2025 business school rankings are based on data from surveys of administrators at 244 business schools as well as surveys of 22,800 students enrolled in the schools’ MBA programs during the previous three academic years.

"The schools that made our lists for 2025 share four characteristics that inform our criteria for designating them as 'best': excellent academics, robust experiential learning components, outstanding career services, and positive feedback about them from enrolled students we surveyed," Rob Franek, The Princeton Review's editor-in-chief, said in a press release. "No b-school is best overall or best for all students, but to all students considering earning an MBA, we highly recommend these b-schools and salute them for their impressive programs."

Rice's finance program has ranked in the top 10 for eight consecutive years, and its online MBA has ranked in the top five for four years.

Rice and the University of Houston also claimed top marks on the Princeton Review's entrepreneurship rankings. Rice ranks as No. 1 on the Top 50 Entrepreneurship: Grad list, and the University of Houston ranked No. 1 on Top 50 Entrepreneurship: Ugrad. Read more here.

Houston named ‘star’ metro for artificial intelligence in new report

eyes on AI

A new report declares Houston one of the country’s 28 “star” hubs for artificial intelligence.

The Houston metro area appears at No. 16 in the Brookings Institution’s ranking of metros that are AI “stars.” The metro areas earned star status based on data from three AI buckets: talent, innovation and adoption. Only two places, the San Francisco Bay Area and Silicon Valley, made Brookings’ “superstar” list.

According to Brookings, the Houston area had 11,369 job postings in 2024 that sought candidates with AI skills, 210 AI startups (based on Crunchbase data from 2014 to 2024), and 113 venture capital deals for AI startups (based on PitchBook data from 2023 to 2024).

A number of developments are boosting Houston’s AI profile, such as:

Brookings also named Texas’s three other major metros as AI stars:

  • No. 11 Austin
  • No. 13 Dallas-Fort Worth
  • No. 40 San Antonio

Brookings said star metros like Houston “are bridging the gap” between the two superstar regions and the rest of the country. In 2025, the 28 star metros made up 46 percent of the country’s metro-area employment but 54 percent of AI job postings. Across the 28 metros, the number of AI job postings soared 139 percent between 2018 and 2025, according to Brookings.

Around the country, dozens of metros fell into three other categories on Brookings’ AI list: “emerging centers” (14 metros), “focused movers” (29 metros) and “nascent adopters” (79 metros).

Forecasting retail sales just got smarter, thanks to Google searches

houston voices

Imagine being able to predict the future of retail sales — not with months-old economic reports, but with real-time digital breadcrumbs left behind by consumers. Thanks to new research from K. Ramesh (Rice Business) and Gary Lind (University of Pittsburgh), that future is already here.

Key findings

  • Search trends predict future retail revenue — up to three quarters ahead.
  • Markets don’t fully price in search-based insights, especially before earnings announcements.
  • Trading strategies using search data outperform traditional asset-pricing models by 2–3%.
  • Analysts often underuse this data, resulting in predictable forecast errors.
  • At the macro level, search trends closely track — and often lead — official retail sales and GDP.

Their study shows that Google search trends are powerful predictors of consumer demand, capable of forecasting U.S. retail sales up to three quarters in advance. The implications span industries and audiences — from Wall Street traders to Main Street retailers, and from data-driven CFOs to curious business students.

A smarter, faster crystal ball for retail demand

Retail sales drive nearly 70% of U.S. gross domestic product (GDP), making them one of the most important indicators of economic health. Yet traditional forecasting relies heavily on backward-looking data and broad economic indicators. Ramesh and Lind’s work offers a leap forward: search data from Google Trends — publicly available and easy to use — can offer a faster, more precise signal of where sales are headed.

“If you want to understand consumer demand,” says Ramesh, the Herbert S. Autrey Professor of Accounting at Rice Business, “look at what people are searching for — not just what companies report after the fact. These digital footprints can tell us where revenue is going, often before the market catches up.”

This low-cost approach stands in stark contrast to expensive alternatives, such as satellite images of parking lots, in-store foot traffic from mobile data, or retail scanner feeds — tools often reserved for hedge funds and large institutional investors. Google Trends offers a scalable, accessible option for anyone seeking insight into consumer behavior.

Why this matters for investors and analysts

The researchers analyzed search patterns for nearly 200 publicly traded U.S. retail companies between 2004 and 2019. They found that firms with rising search volumes tend to report higher revenues — often well before analysts or investors react.

In fact, investment strategies built around these trends earned 2–3% higher returns than traditional models would predict. And most of these gains were concentrated around earnings announcements — a sign that markets were slow to recognize what search data had already revealed.

The advantage is even more striking for companies that fly under Wall Street’s radar. For firms with limited analyst coverage, the predictive power of search data on stock performance was more than 80% stronger.

A new tool for analysts — if they’ll use it

Despite the clear signal in the data, the study finds that analysts routinely fail to incorporate search-based insights into their forecasts. That gap translates into missed revenue predictions and market inefficiencies — which sophisticated investors can exploit.

“The search data are out there,” says Lind, a Rice Business Ph.D. ’19 graduate now on faculty at Pitt Business. “They’re public, powerful, and free. Analysts who ignore them are missing an opportunity.”

The impact of this research extends well beyond equity markets. By aggregating Google search data across the retail sector, the authors found strong alignment with U.S. Census retail sales figures and GDP trends. In other words, these digital signals reflect not just firm-level interest, but macroeconomic momentum.

A data wake-up call

This makes search trends a potentially valuable early-warning system for policymakers, central banks, and anyone responsible for interpreting the economic landscape. During volatile or uncertain periods, such tools could offer precious foresight into shifting consumer behavior.

In a digital era where consumers research before they shop — whether online or in-store — it’s no surprise that their Google queries leave valuable clues. What’s surprising is how often businesses, investors, and even economists still overlook them, Ramesh says. “Search data is a goldmine. And it's just sitting there, waiting to be used.”

---

This article originally appeared on Rice Business Wisdom.

Lind and Ramesh, “Using Internet Search Data to Predict Aggregate Retail Sales and Enhance Firm-Level Revenue Expectations,” Contemporary Accounting Research (April 2025): 1-32. https://doi.org/10.1111/1911-3846.13043.

View All Listings